Filing Flows › Comparisons › ATRC vs BVS
AtriCure vs Bioventus: ATRC and BVS compared
AtriCure is the larger company: $154M of revenue in its latest quarter (Q3 2026) against $142M for Bioventus (Q3 2026). AtriCure is growing faster (+15% against +3% a year earlier). Bioventus is more profitable, with an operating margin of 6.8% against 2.8%.
Where the money goes: ATRC and BVS
AtriCure (ATRC) · Q3 2026
AtriCure, Q3 2026: revenue $154M (+15% year over year), operating margin 2.8%, net earnings $4.1M, operating cash flow $30.3M. The chart follows the revenue to costs, profit and cash.
Bioventus (BVS) · Q3 2026
Bioventus, Q3 2026: revenue $142M (+3% year over year), operating margin 6.8%, net earnings $6.0M, operating cash flow $20.7M. The chart follows the revenue to costs, profit and cash.
| AtriCure (ATRC) | Bioventus (BVS) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $154M | $142M |
| Revenue growth, Y/Y | +15% | +3% |
| Gross margin | 77.3% | 68.2% |
| Operating margin | 2.8% | 6.8% |
| Net earnings | $4.1M | $6.0M |
| Net margin | 2.6% | 4.2% |
| Operating cash flow | $30.3M | $20.7M |
| Free cash flow | $23.9M | $20.3M |
Questions
Which is bigger, AtriCure or Bioventus?
AtriCure is the larger company: $154M of revenue in its latest quarter (Q3 2026) against $142M for Bioventus (Q3 2026).
Is AtriCure or Bioventus growing faster?
AtriCure is growing faster (+15% against +3% a year earlier).
Which is more profitable, AtriCure or Bioventus?
Bioventus is more profitable, with an operating margin of 6.8% against 2.8%.
More: AtriCure earnings · how AtriCure makes money · Bioventus earnings · how Bioventus makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 4, 2026; 10-Q filed Nov 2, 2026). Fiscal quarters can end on different dates. Not investment advice.